Metabolic and anatomic characteristics of benign and malignant adrenal masses on positron emission tomography/computed tomography: a review of literature

Asha Kandathil, Ka Kit Wong, Daniel J. Wale, Maria Chiara Zatelli, Anna Margherita Maffione, Milton D. Gross, Domenico Rubello

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

PET/CT with 18F-fluorodeoxyglucose (FDG) or using different radiocompounds has proven accuracy for detection of adrenal metastases in patients undergoing cancer staging. It can assist the diagnostic work-up in oncology patients by identifying distant metastases to the adrenal(s) and defining oligometastatic disease that may benefit from targeted intervention. In patients with incidentally discovered adrenal nodules, so-called adrenal “incidentaloma” FDG PET/CT is emerging as a useful test to distinguish benign from malignant etiology. Current published evidence suggests a role for FDG PET/CT in assessing the malignant potential of an adrenal lesion that has been ‘indeterminately’ categorized with unenhanced CT, adrenal protocol contrast-enhanced CT, or chemical-shift MRI. FDG PET/CT could be used to stratify patients with higher risk of malignancy for surgical intervention, while recommending surveillance for adrenal masses with low malignant potential. There are caveats for interpretation of the metabolic activity of an adrenal nodule on PET/CT that may lead to false-positive and false-negative interpretation. Adrenal lesions represent a wide spectrum of etiologies, and the typical appearances on PET/CT are still being described, therefore our goal was to summarize the current diagnostic strategies for evaluation of adrenal lesions and present metabolic and anatomic appearances of common and uncommon adrenal lesions. In spite of the emerging role of PET/CT to differentiate benign from malignant adrenal mass, especially in difficult cases, it should be emphasized that PET/CT is not needed for most patients and that many diagnostic problems can be resolved by CT and/or MR imaging.

Original languageEnglish (US)
Pages (from-to)6-26
Number of pages21
JournalEndocrine
Volume49
Issue number1
DOIs
StatePublished - May 1 2015

Fingerprint

Neoplasm Metastasis
Neoplasm Staging
Fluorodeoxyglucose F18
Positron Emission Tomography Computed Tomography
Neoplasms
CT protocol
Adrenal incidentaloma

Keywords

  • Adrenocortical adenoma
  • CT
  • Incidentaloma
  • MRI
  • PET/CT
  • Pheochromocytoma

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Metabolic and anatomic characteristics of benign and malignant adrenal masses on positron emission tomography/computed tomography : a review of literature. / Kandathil, Asha; Wong, Ka Kit; Wale, Daniel J.; Zatelli, Maria Chiara; Maffione, Anna Margherita; Gross, Milton D.; Rubello, Domenico.

In: Endocrine, Vol. 49, No. 1, 01.05.2015, p. 6-26.

Research output: Contribution to journalReview article

Kandathil, Asha ; Wong, Ka Kit ; Wale, Daniel J. ; Zatelli, Maria Chiara ; Maffione, Anna Margherita ; Gross, Milton D. ; Rubello, Domenico. / Metabolic and anatomic characteristics of benign and malignant adrenal masses on positron emission tomography/computed tomography : a review of literature. In: Endocrine. 2015 ; Vol. 49, No. 1. pp. 6-26.
@article{4109f486a9534397828495f718f14323,
title = "Metabolic and anatomic characteristics of benign and malignant adrenal masses on positron emission tomography/computed tomography: a review of literature",
abstract = "PET/CT with 18F-fluorodeoxyglucose (FDG) or using different radiocompounds has proven accuracy for detection of adrenal metastases in patients undergoing cancer staging. It can assist the diagnostic work-up in oncology patients by identifying distant metastases to the adrenal(s) and defining oligometastatic disease that may benefit from targeted intervention. In patients with incidentally discovered adrenal nodules, so-called adrenal “incidentaloma” FDG PET/CT is emerging as a useful test to distinguish benign from malignant etiology. Current published evidence suggests a role for FDG PET/CT in assessing the malignant potential of an adrenal lesion that has been ‘indeterminately’ categorized with unenhanced CT, adrenal protocol contrast-enhanced CT, or chemical-shift MRI. FDG PET/CT could be used to stratify patients with higher risk of malignancy for surgical intervention, while recommending surveillance for adrenal masses with low malignant potential. There are caveats for interpretation of the metabolic activity of an adrenal nodule on PET/CT that may lead to false-positive and false-negative interpretation. Adrenal lesions represent a wide spectrum of etiologies, and the typical appearances on PET/CT are still being described, therefore our goal was to summarize the current diagnostic strategies for evaluation of adrenal lesions and present metabolic and anatomic appearances of common and uncommon adrenal lesions. In spite of the emerging role of PET/CT to differentiate benign from malignant adrenal mass, especially in difficult cases, it should be emphasized that PET/CT is not needed for most patients and that many diagnostic problems can be resolved by CT and/or MR imaging.",
keywords = "Adrenocortical adenoma, CT, Incidentaloma, MRI, PET/CT, Pheochromocytoma",
author = "Asha Kandathil and Wong, {Ka Kit} and Wale, {Daniel J.} and Zatelli, {Maria Chiara} and Maffione, {Anna Margherita} and Gross, {Milton D.} and Domenico Rubello",
year = "2015",
month = "5",
day = "1",
doi = "10.1007/s12020-014-0440-6",
language = "English (US)",
volume = "49",
pages = "6--26",
journal = "Endocrine",
issn = "1355-008X",
publisher = "Humana Press",
number = "1",

}

TY - JOUR

T1 - Metabolic and anatomic characteristics of benign and malignant adrenal masses on positron emission tomography/computed tomography

T2 - a review of literature

AU - Kandathil, Asha

AU - Wong, Ka Kit

AU - Wale, Daniel J.

AU - Zatelli, Maria Chiara

AU - Maffione, Anna Margherita

AU - Gross, Milton D.

AU - Rubello, Domenico

PY - 2015/5/1

Y1 - 2015/5/1

N2 - PET/CT with 18F-fluorodeoxyglucose (FDG) or using different radiocompounds has proven accuracy for detection of adrenal metastases in patients undergoing cancer staging. It can assist the diagnostic work-up in oncology patients by identifying distant metastases to the adrenal(s) and defining oligometastatic disease that may benefit from targeted intervention. In patients with incidentally discovered adrenal nodules, so-called adrenal “incidentaloma” FDG PET/CT is emerging as a useful test to distinguish benign from malignant etiology. Current published evidence suggests a role for FDG PET/CT in assessing the malignant potential of an adrenal lesion that has been ‘indeterminately’ categorized with unenhanced CT, adrenal protocol contrast-enhanced CT, or chemical-shift MRI. FDG PET/CT could be used to stratify patients with higher risk of malignancy for surgical intervention, while recommending surveillance for adrenal masses with low malignant potential. There are caveats for interpretation of the metabolic activity of an adrenal nodule on PET/CT that may lead to false-positive and false-negative interpretation. Adrenal lesions represent a wide spectrum of etiologies, and the typical appearances on PET/CT are still being described, therefore our goal was to summarize the current diagnostic strategies for evaluation of adrenal lesions and present metabolic and anatomic appearances of common and uncommon adrenal lesions. In spite of the emerging role of PET/CT to differentiate benign from malignant adrenal mass, especially in difficult cases, it should be emphasized that PET/CT is not needed for most patients and that many diagnostic problems can be resolved by CT and/or MR imaging.

AB - PET/CT with 18F-fluorodeoxyglucose (FDG) or using different radiocompounds has proven accuracy for detection of adrenal metastases in patients undergoing cancer staging. It can assist the diagnostic work-up in oncology patients by identifying distant metastases to the adrenal(s) and defining oligometastatic disease that may benefit from targeted intervention. In patients with incidentally discovered adrenal nodules, so-called adrenal “incidentaloma” FDG PET/CT is emerging as a useful test to distinguish benign from malignant etiology. Current published evidence suggests a role for FDG PET/CT in assessing the malignant potential of an adrenal lesion that has been ‘indeterminately’ categorized with unenhanced CT, adrenal protocol contrast-enhanced CT, or chemical-shift MRI. FDG PET/CT could be used to stratify patients with higher risk of malignancy for surgical intervention, while recommending surveillance for adrenal masses with low malignant potential. There are caveats for interpretation of the metabolic activity of an adrenal nodule on PET/CT that may lead to false-positive and false-negative interpretation. Adrenal lesions represent a wide spectrum of etiologies, and the typical appearances on PET/CT are still being described, therefore our goal was to summarize the current diagnostic strategies for evaluation of adrenal lesions and present metabolic and anatomic appearances of common and uncommon adrenal lesions. In spite of the emerging role of PET/CT to differentiate benign from malignant adrenal mass, especially in difficult cases, it should be emphasized that PET/CT is not needed for most patients and that many diagnostic problems can be resolved by CT and/or MR imaging.

KW - Adrenocortical adenoma

KW - CT

KW - Incidentaloma

KW - MRI

KW - PET/CT

KW - Pheochromocytoma

UR - http://www.scopus.com/inward/record.url?scp=84939891860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939891860&partnerID=8YFLogxK

U2 - 10.1007/s12020-014-0440-6

DO - 10.1007/s12020-014-0440-6

M3 - Review article

C2 - 25273320

AN - SCOPUS:84939891860

VL - 49

SP - 6

EP - 26

JO - Endocrine

JF - Endocrine

SN - 1355-008X

IS - 1

ER -